Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.0
29.62%
60%
—
7.94%
60%
—
5 Years
Score5.0
Net Growth29.62%
Net Trend60%
Net Income Consistency—
Rev Growth7.94%
Rev Trend60%
Revenue Consistency—
Aligos Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue went from -$ 10M to $ 2M and net income went from -$ 108M to -$ 24M. Revenue increased in 3 of those 5 years; net income in 3.
Aligos Therapeutics Inc currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 7.00 | — |
1 Year2025-08-12 | $ 7.43 | -5.85% |
5 Years2021-08-12 | $ 393.25 | -98.22% |
All Time2020-10-16 | $ 371.25 | -98.11% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-10-16 |
|---|---|---|---|---|
| Price | $ 7.00 | $ 7.43 | $ 393.25 | $ 371.25 |
| Return | — | -5.85% | -98.22% | -98.11% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 4M | -$ 90M | $ 55M |
| 2025 | $ 2M | -$ 24M | $ 77M |
| 2024 | $ 3M | -$ 131M | $ 56M |
| 2023 | $ 15M | -$ 87M | $ 135M |
| 2022 | $ 13M | -$ 96M | $ 125M |
| 2021 | $ 4M | -$ 128M | $ 190M |
| IPO2020 | -$ 10M | -$ 108M | $ 243M |
Explore beyond ALGS
You're looking at Aligos Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
